Delivery Order SPE2DB25D2204-SPE2DB25FTGVV
- Not listed
- The Defense Logistics Agency awarded a $13,150.18 delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen injectors on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management, reflecting the federal...
- The Defense Logistics Agency awarded a delivery order valued at $42,562.60 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $11,574.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on April 24, 2025, with an ultimate completion date of April 25, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injections, valued at $6,035.72. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a $5,621.91 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with an ultimate completion date of September 17, 2025. This firm fixed price contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $20,034.10 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on August 29, 2025, with completion targeted for September 2, 2025. This firm fixed price, non-set-aside contract represents a discrete delivery under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist...
- The Defense Logistics Agency awarded a delivery order valued at $8,512.52 to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This firm fixed-price, non-competitive set-aside delivery order is scheduled for completion by July 29, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, representing part of the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 ml pens with a ceiling value of $2,726.72. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $20,840.52 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injections on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used for weight management treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $3,134.95 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pens on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitive, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication used for weight management, reflecting the federal...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGVVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,888.06 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pens on August 6, 2025, with an ultimate completion date of August 7, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist used in weight management therapy, reflecting the federal government's procurement of modern pharmaceutical treatments for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical supply needs, supplying a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide. The parent IDC enables the contractor to fulfill diverse pharmaceutical requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through a flexible procurement vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.9k | 8/6/25 |